RS-5614

N/A

Report date: 2024/04/01 11:47:56
NME

Base Information

Drug NameRS-5614
Drug Alias NameTM-5614TM5614RS-5614RS5614
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPlasminogen activator inhibitor 1 inhibitors
TargetsPlasminogen activator inhibitor 1
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Lung Diseases, InterstitialCarcinoma, Non-Small-Cell Lung +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTurkeyJapan
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesRenascience Inc
China Registration ClassN/A

Develop Information

Active CompaniesRenascience IncDaiichi Sankyo Co Ltd
Inactive CompaniesNorthwestern University
Active IndicationsCoronavirus Disease 2019 (COVID-19)Lung Diseases, InterstitialCarcinoma, Non-Small-Cell Lung +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A